-

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Talem Health. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Physicians 

Boston University School of Medicine designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

This educational activity has been provided by Continuing Nursing Education Provider Unit, Boston University School of Medicine and jointly-provided by Talem Health.

Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Contact Hours: 0.25 of which 0.25 are eligible for pharmacology credit

• Medical_Professionals
• Medical_students
• Nurses

Primary care remains the main access point for major depressive disorder (MDD) treatment in the United States, yet major gaps are evident at each step along the management continuum, including delayed diagnosis, inadequate monitoring, and insufficient use of evidence-based treatment. The rural setting presents barriers to the management of MDD as patients have limited access to psychiatrists and other mental health providers. Thus, primary care practitioners in rural settings are likely the sole providers of MDD management, suggesting that education efforts are needed that specifically target the unique challenges these practitioners face when managing MDD.

Target Audience

This program is designed specifically for primary care physicians, nurse practitioners, physician assistants, and other healthcare providers in a rural health setting.

Objectives

After completing this activity, participants should be better able to:

         - Integrate measurement-based tools into the individualized treatment of MDD to better detect and manage inadequate treatment response, side effects, and residual symptoms.

Dr. Gaynes: grant support: M-3 Information. Dr. Gaynes does not plan to discuss unlabeled/investigational uses of a commercial product.

Dr. Klinkman: has no relevant financial relationships to disclose. Dr. Klinkman does not plan to discuss unlabeled/investigational uses of a commercial product.

Dr. Vanacore: has no relevant financial relationships to disclose. Dr. Vanacore does not plan to discuss unlabeled/investigational uses of a commercial product.

USD

Group registrations not allowed

Accompanying persons not allowed

We don’t accept Online Abstracts

Submission Info

Contact No.: 617.638.4605

Email: cme@bu.edu

Contact No.: 617.638.4605

Email: cme@bu.edu